Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
224 people get CLVS articles and Market Currents by email alert.
Get email alerts on CLVS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Business Wire (May 16, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Feb 28, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Jan 7, 2013)
-
Business Wire (Jan 2, 2013)
-
Business Wire (Nov 12, 2012)
-
-
Business Wire (Nov 8, 2012)
-
-
Business Wire (Nov 5, 2012)
-
Business Wire (Oct 18, 2012)
-
Business Wire (Aug 29, 2012)
To learn more about Seeking Alpha Pro, click here.
-
Clovis Oncology Raises $130 Million In IPOThe Burrill Report • Thu, Nov 17, 2011 -
-
-
-
-
-
-
-
-
-
-
-
-
-
Tracking IPO PerformanceBespoke Investment Group • Fri, Mar 9, 2012 -
-
-
-
9 IPOs Planned For This WeekRenaissance Capital IPO Research • Tue, Nov 15, 2011
-
Business Wire (May 16, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Feb 28, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Jan 7, 2013)
-
Business Wire (Jan 2, 2013)
-
at MarketWatch.com (Nov 12, 2012)
-
at CNBC.com (Nov 12, 2012)
-
Business Wire (Nov 12, 2012)
-
Business Wire (Nov 8, 2012)
-
Business Wire (Nov 5, 2012)
-
Business Wire (Oct 18, 2012)
-
Business Wire (Aug 29, 2012)
-
at Fox Business (Aug 17, 2012)
-
at Fox Business (Aug 17, 2012)
-
at Fox Business (Aug 17, 2012)
-
at Fox Business (Aug 17, 2012)
CLVS vs. ETF Alternatives
Company Description
Currently, there's no company description for CLVS.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, May 7, 8:27 AM Clovis Oncology (CLVS): Q1 EPS of -$0.60 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, March 1, 2:23 AM Clovis Oncology (CLVS): Q4 EPS of -$0.81 beats by $0.03. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, November 12, 2012, 12:45 PM Midday top 10 gainers: TIE +42%. STV +32%. MYRX +18%. CPSS +17%. PZZI +15%. SRPT +13%. EVI +13%. JEF +12%. GILD +12%. CXS +12%. Midday top 10 Losers: CLVS -33%. GALE -33%. STSI -23%. RECV -17%. BZH -15%. ET -14%. XIDE -13%. NKTR -12%. MEET -12%. IDN -11%. Comment!
-
Monday, November 12, 2012, 9:10 AM
Premarket gainers: TIE +43%. JEF +24%. MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%. SQNM +7%. LUK +7%. RIMM +6%. NKTR +6%. STV +5%. DNDN +5%. CEL +5%. PCP +5%.
Losers: CLVS -41%. STSI -20%. NBG -11%. Comment! [On the Move] - Monday, November 12, 2012, 8:39 AM Clovis Oncology (CLVS) shares collapse 42% after its CO-101 treatment failed to prolong the survival of patients with pancreatic cancer vs gemcitabine in a phase III study. Clovis is now ending the development of the drug pending further evaluation of the trial data. Comment! [Healthcare, On the Move]
- Wednesday, August 8, 2012, 6:33 AM Clovis Oncology (CLVS): Q2 EPS of -$0.61 in-line. (PR) Comment! [Earnings, Healthcare]
- Thursday, March 8, 2012, 11:00 AM Recent IPO Clovis Oncology (CLVS -9.8%) takes a hit after posting a $14.9M Q4 loss, despite showing improvement over the prior year period. Bottom line margins were hit as R&D expenses nearly doubled due to the expanded development activities for its CO-101 and CO-1686 drugs, as well as the in-licensing of Rucaparib from Pfizer in mid 2011. Comment! [Healthcare, Earnings, On the Move]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.